The constitutively active BCR-ABL1 tyrosine kinase, found in t (9; 22)(q34; q11)
chromosomal translocation-derived leukemia, initiates an extremely complex signaling …

Deregulated activity of BCR-ABL1, a nonreceptor tyrosine kinase encoded by the fusion
gene resulting from the t (9; 22)(q34; q11) chromosomal translocation, is thought to be the …

The introduction of ABL Tyrosine Kinase Inhibitors (TKIs) has significantly improved the
outcome of Chronic Myeloid Leukemia (CML) patients that, in large part, achieve satisfactory …

Chronic myeloid leukemia (CML) is a clonal hematopoietic disorder characterized by the
presence of the Philadelphia chromosome which resulted from the reciprocal translocation …

With an annual incidence of about ten in 1,000,000 people, chronic myeloid leukemia (CML)
accounts for most cases of myeloproliferative disease and for 20% of all leukemias. While …

BCR-ABL1 plays a key role in the pathogenesis of chronic myeloid leukemia (CML), and it
has been investigated as a druggable target of tyrosine kinase inhibitors (TKIs) over two …

Aberrant tyrosine kinase activity plays a critical role in many hematologic disorders,
including chronic myeloid leukemia characterized by the constitutive activity of BCR-ABL …

Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine
kinase, has served as a paradigm for successful application of molecularly targeted cancer …

Chronic myeloid leukemia (CML) is caused by the formation of the BCR-ABL fusion protein
as a result of the t (9; 22) chromosomal translocation. The elucidation of its molecular …

Background: Chronic myelogenous leukemia (CML) and a subset of acute lymphoblastic
leukemia (ALL) are caused by the t (9; 22)(q34; q11. 2) chromosome translocation, resulting …